Novo Nordisk A/S Sponsored ADR (NVO)
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up
Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes and Obesity care products.
Novo Nordisk: Among The Best Opportunities Of The Moment (Rating Upgrade)
Novo Nordisk A/S dominates in diabetes and weight-loss drugs, particularly with semaglutide, making it a strong buy. Record investments in 2024 to enhance supply chain and production capacity highlight Novo Nordisk's commitment to meeting soaring demand. Double-digit growth in revenue and operating income expected for 2025, with promising guidance and a current undervaluation based on a P/E Ratio FWD of just 22x.
Novo Nordisk gains on Q4 earnings beat
Novo Nordisk (NYSE:NVO) shares moved higher as the Danish drugmaker posted better-than-expected financial results for the fourth quarter driven by demand for its obesity drugs. The company posted a net profit of 28.23 billion Danish kroner (about US$4 billion), ahead of analysts' expectations of 26.09 billion Danish kroner.
Novo Nordisk Stock Pops on Upbeat Earnings
Pharmaceutical concern Novo Nordisk A/S (NYSE:NVO) is up 4.9% at $86.63 at last glance.
Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Novo Nordisk A/S today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn and a 26% rise in operating profit to ~$17.91bn for 2024. The company's GLP-1 drugs, Ozempic and Wegovy, drove significant revenue growth, accounting for 61% of total sales, despite some market challenges. Insulin sales also outperformed. Novo's next-gen candidate, CagriSema, has shown promising weight loss results, though it fell short of some expectations, impacting the stock price. Management outlined plans to submit for approval in '26.
Novo Nordisk CEO Lars Fruergaard Jørgensen on Q4 results, Wegovy demand and drug pipeline outlook
CNBC's Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly earnings results, demand for Wegovy, drug pipeline outlook, Cagrisema results, obesity drug pricing, state of Medicare drug price negotiations, and more.
Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For Hybrid Weight Loss Drug In 2026
On Wednesday, Novo Nordisk A/S NVO reported sales of roughly $12.25 billion (85.68 billion Danish kroner) for the fourth quarter of 2024, beating the consensus of $11.34 billion (79.73 billion Danish Kroner).
Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double
Novo Nordisk's (NVO) U.S.-listed shares are rising 4% in premarket trading Wednesday after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid "intensifying competition."
Novo Nordisk says it's not immune to potential Trump tariffs, but business is well-positioned
Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, its chief executive said on Wednesday, but it is confident its business is well-positioned.
Novo Nordisk sales beat estimates, but the story wasn't Ozempic
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn't its wildly popular weight-loss drugs.
Novo Nordisk's new CagriSema study to focus on dose escalation and trial length
Novo Nordisk on Wednesday said its new trial of its next-generation obesity drug candidate CagriSema will look at dose escalation and trial length to further show the drug's potential, after data in December disappointed the market.
Novo Nordisk shares surge as Wegovy sales drive profit beat
Shares of Novo Nordisk climbed 4.5% on Wednesday after the Danish pharmaceutical giant reported a stronger-than-expected fourth-quarter net profit, driven by soaring demand for its obesity treatment, Wegovy. However, the company warned that sales growth could slow in 2025 as competition intensifies in the weight-loss drug market.
